{"entity":{"id":"nct07633873","kind":"trial","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST","aka":[],"tldr":"A phase 3 trial of tislelizumab, paclitaxel / nab-paclitaxel, cisplatin and carboplatin in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","summary":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） is a phase 3, randomised interventional study registered as NCT07633873 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 500 participants, started 2026-06-02 and due to reach its primary completion in 2027-09-30. Interventions recorded: SYS6010 injection; Enlonstobart injection; Tislelizumab injection; Paclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS) assessed by IRC. Lung eligibility wording from the registry: \"Participants with pathologically confirmed locally advanced or metastatic NSCLC\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07633873","url":"https://clinicaltrials.gov/study/NCT07633873"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["tislelizumab","paclitaxel","cisplatin","carboplatin"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07633873","phase":"3","setting":"An Open-label, Multicenter Randomized Phase III Study of SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy as First-Line Treatment for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07633873/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}